Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Yue-Min Nana*, Na Fua, Wen-Juan Wua, Bao-Li Lianga, Rong-Qi Wanga, Su-Xian Zhaoa, Jing-Min Zhaob & Jun Yucda Department of Traditional and Western Medical Hepatology, the Third Hospital of Hebei Medical University, Shijiazhuang, Chinab Department of Pathology, Beijing 302 Hospital, Beijing, Chinac Institute of Digestive Disease and Li Ka Shing Institute of Health Sciences, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kongd Department of Gastroenterology, the First Hospital of Hebei Medical University, Shijiazhuang, China† Correspondence: Yue-Min Nan, Traditional and Western Medical, Department of Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China, +86 311 88602151, +86 311 87023626 nanyuemin@163.comObjective. Currently, no agent has been confirmed as preventing the fibrosing progression of non-alcoholic steatohepatitis (NASH). In this study, rosiglitazone was used in the clinical treatment of insulin resistance in patients with type 2 diabetes mellitus. However, its protective effect on non-alchoholic fibrosing steatohepatitis is not clear. The study aimed to elucidate the effect and the mechanism of rosiglitazone in inhibiting nutrition-related fibrosis in mice. Methods. C57BL6/J mice were fed a high fat, methionine-choline deficient (MCD) diet for 8 weeks to induce hepatic fibrosis, and rosiglitazone was given in the treated group. The effect of rosiglitazone was assessed by comparing the severity of hepatic fibrosis in liver sections, the activation of hepatic stellate cells (HSCs) and the expression of TGF-β1 and connective tissue growth factor (CTGF). Results. At week 8, MCD-diet-induced fibrosing NASH models showed increased serum ALT and AST levels, severe hepatic steatosis, and infiltration of inflammation and fibrosis which, associated with down-regulated PPARγ mRNA and protein expression, up-regulated α-SMA protein expression and enhanced TGF-β1, CTGF mRNA and protein expression. Rosiglitazone significantly lowered serum ALT and AST and it reduced MCD-induced fibrosis by repressing levels of α-SMA protein expression and pro-fibrosis factors TGF-β1 and CTGF. It also restored expression of PPARγ. Conclusions. The present study provides clear morphological and molecular biological evidence of the protective role of rosiglitazone in ameliorating nutritional fibrosing steatohepatitis. Rosiglitazone may ameliorate hepatic fibrosis by activating PPARγ, which can inhibit HSC activation and suppress TGF-β1 and CTGF expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319 · cited 2×
“The strong correlation found between TGF-b1 expression, overexpression of leptin receptor and the degree of hepatic fibrosis suggests that TGF-b1 activation may be one of the mechanisms by which the leptin could contribute to the development of hepatic fibrosis [32,33].”
BackgroundRatziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625 · cited 1×
“Our results were also supported by the evidence that rosiglitazone protected mice from MCD dietinduced steatohepatitis [12] and patients with NASH with reduced inflammation and liver injury [13,14].”
ResultSaxena, N. K., Ikeda, K., Rockey, D. C., Friedman, S. L., & Anania, F. A. (2002) · Hepatology · doi:10.1053/jhep.2002.32029 · Cited by 382 · cited 1×
“Several studies have shown that leptin exerts a pro-fibrogenic activity that acts directly on hepatic stellate cells [29,30] to increase expression of TGF-b1 and a-SMA.”
BackgroundHepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325 · cited 11×
“The aim of this study was to investigate the effect of rosiglitazone on activation of HSCs and expression of PPARg, TGF-b1 and CTGF in mice with hepatic fibrosis induced by the MCD diet [6].”
BackgroundInfluentialGalli, A., Crabb, D., Price, D., Ceni, E., Salzano, R., Surrenti, C., & Casini, A. (2000) · Hepatology · doi:10.1002/hep.510310117 · Cited by 197 · cited 1×
“[11] demonstrated that rosiglitazone could prevent liver fibrosis induced by dimethyl nitroxide (DMN), CCl4 and bile duct ligation (BDL) in murine.”
BackgroundPPAR Gamma and Hepatic Stellate Cells
Hazra, S., Miyahara, T., Rippe, R. A., & Tsukamoto, H. (2004) · Comparative Hepatology · doi:10.1186/1476-5926-2-s1-s7 · Cited by 66
Cited by
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 311
PPARs and nonalcoholic fatty liver disease
Liss, K. H. H., & Finck, B. N. (2017) · Biochimie · doi:10.1016/j.biochi.2016.11.009 · Cited by 275
Pharmacological intervention in hepatic stellate cell activation and hepatic fibrosis
Schon, H.-T., Bartneck, M., Borkham-Kamphorst, E., Nattermann, J., Lammers, T., Tacke, F., & Weiskirchen, R. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00033 · Cited by 97
“In line, rosiglitazone (Avandia, GlaxoSmithKline) – a thiazolidinedione – could both reduce hepatic fibrosis in mice by downregulation of the protein expression of α-SMA, TGF-β1, and CTGF and re-establish the expression of PPARγ (Nan et al., 2009).”
BackgroundZhong, X., & Liu, H. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13853 · Cited by 60
Metadata
- Authors
- Nan, Y.-M., Fu, N., Wu, W.-J., Liang, B.-L., Wang, R.-Q., Zhao, S.-X., Zhao, J.-M., & Yu, J.
- Venue
- Scandinavian Journal of Gastroenterology
- Publisher
- Informa UK Limited
- Published
- 2009-01
- Volume
- 44
- Issue
- 3
- Pages
- 358-365
- ISSN
- 0036-5521 (ISSN-L)
- 1502-7708
- OpenAlex
- W2020195767
- Cited by
- 75
- References
- 7
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. https://app.cochat.ai/papers/10.1080/00365520802530861
- The paper
- Nan, Y.-M., Fu, N., Wu, W.-J., Liang, B.-L., Wang, R.-Q., Zhao, S.-X., Zhao, J.-M., & Yu, J. (2009). Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. Scandinavian Journal of Gastroenterology. https://doi.org/10.1080/00365520802530861
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.